Eagle pharmaceuticals, inc. (EGRX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Jun'13Mar'13
Revenue:
Total revenue

46,020

48,258

41,147

56,702

49,785

56,053

51,337

59,296

46,626

46,785

63,021

50,108

76,793

81,140

37,833

40,918

29,591

18,180

5,736

6,002

36,309

5,600

2,811

5,792

5,005

5,492

5,075

2,480

Operating expenses:
Cost of product sales

4,765

8,025

12,137

18,175

9,554

12,456

8,621

14,074

7,223

9,224

4,815

8,910

10,765

9,837

6,000

7,181

12,767

-

-

-

-

1,782

-

-

-

-

-

-

Cost of royalty revenue

3,038

3,566

2,785

3,109

3,546

6,102

4,370

4,485

4,585

4,483

6,850

4,910

7,229

8,982

4,425

4,292

1,822

-5,164

3,753

3,348

5,948

2,707

2,175

1,556

3,360

4,624

2,925

1,313

Research and development

9,427

11,306

10,172

8,957

6,375

5,859

5,975

15,265

17,320

9,444

8,954

6,684

7,525

15,762

3,207

3,799

5,521

8,781

6,911

5,878

6,285

3,986

5,888

4,545

3,794

2,589

1,632

2,525

Selling, general and administrative

24,755

22,464

18,537

17,228

18,141

15,451

13,878

15,987

15,193

12,889

16,669

23,280

18,578

17,550

11,661

11,990

12,128

5,608

5,460

5,111

3,986

3,690

3,854

2,673

1,454

1,344

1,251

2,948

Restructuring charge

-

-

0

0

-

-

91

7,388

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of asset

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,750

0

0

0

0

0

-

-

-

-

-

-

Asset impairment charge

-

-

0

0

-

-

0

2,704

-

-

7,235

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

-

-

0

0

-

-

0

-790

-

-

-6,452

422

-

-

232

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

41,985

45,361

43,631

47,469

37,616

40,327

32,935

59,113

44,321

36,343

38,071

44,206

44,097

52,856

25,525

27,262

30,488

16,987

16,124

14,337

16,219

12,165

11,917

8,774

8,608

8,557

3,815

6,786

Professional fee benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,993

-

Income from operations

4,035

2,897

-2,484

9,233

12,169

15,726

18,402

183

2,305

10,442

24,950

5,902

32,696

28,284

12,308

13,656

-897

1,193

-10,388

-8,335

20,090

-6,565

-9,106

-2,982

-3,603

-3,065

1,259

-4,306

Interest income

346

468

570

637

494

121

9

1

27

39

35

14

3

7

26

30

21

2

8

8

7

1

4

18

8

1

1

0

Interest expense

889

707

628

665

686

617

743

701

675

542

527

40

27

-

-

-

0

2

5

3

1

1

2

5

1

0

16

144

Amortization of deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

38

28

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

436

327

Change in value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

383

191

15

0

Other expense

-6,500

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

35

-

-

0

2

Total other expense, net

-7,043

461

-58

-28

-192

-496

-734

-700

-648

-503

-492

-26

-24

6

23

27

20

0

3

5

6

0

2

48

-376

-190

-505

-497

(Loss) Income before income tax benefit (provision)

-3,008

3,358

-2,542

9,205

11,977

15,230

17,668

-517

1,657

9,939

24,458

5,876

32,672

28,290

12,331

13,683

-877

1,193

-10,385

-8,330

20,096

-6,565

-9,104

-2,934

-3,979

-3,255

754

-4,803

Income tax benefit (provision)

-137

2,353

-152

2,480

3,004

2,642

3,628

-3,176

-959

854

9,027

1,373

9,748

-29,008

379

584

19

-25

-218

-153

399

-1,059

0

0

-1,295

0

0

0

Less dividends on Series A, B, B-1 and C Convertible Preferred Stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

534

1,132

1,074

810

Net income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,506

-9,104

-2,934

-3,218

-4,387

-320

-5,614

Net (Loss) Income

-2,871

1,005

-2,390

6,725

8,973

12,588

14,040

2,659

2,616

9,085

15,431

4,503

22,924

57,298

11,952

13,099

-896

1,218

-10,167

-8,177

19,697

-5,506

-9,104

-2,934

-2,684

-3,255

754

-4,803

(Loss) Earnings per share attributable to common stockholders:
Basic (in usd per share)

-0.21

0.08

-0.17

0.49

0.64

0.86

0.94

0.18

0.18

0.61

1.03

0.30

1.50

3.69

0.77

0.84

-0.06

-0.03

-0.65

-0.53

1.38

-0.39

-0.65

-0.21

-0.36

-1.44

-

-

Diluted (in usd per share)

-0.21

0.08

-0.17

0.48

0.62

0.84

0.91

0.17

0.17

0.59

0.98

0.28

1.42

3.49

0.73

0.80

-0.06

0.03

-0.65

-0.53

1.31

-0.39

-0.65

-0.21

-0.36

-1.44

-

-

Weighted average number of common shares outstanding:
Basic (in shares)

13,667

13,642

13,668

13,782

13,925

14,364

15,011

14,879

14,819

14,885

15,047

15,219

15,257

15,291

15,570

15,636

15,636

15,616

15,589

15,546

14,247

14,032

14,021

14,020

8,862

-

-

-

Diluted (in shares)

13,667

14,312

13,668

14,156

14,418

14,706

15,483

15,446

15,478

15,602

15,764

16,100

16,165

17,183

16,450

16,466

15,636

18,837

15,589

15,546

15,041

14,032

14,021

14,020

8,862

-

-

-

Loss per share attributable to common stockholders Basic and diluted (in usd per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.11

-1.84

Weighted average common shares outstanding Basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,048

3,048

Product sales
Total revenue

17,694

15,421

14,659

29,437

14,472

20,343

16,163

23,041

10,838

10,432

6,905

12,704

15,286

9,080

7,837

9,607

14,122

2,868

3,314

3,730

3,056

1,506

877

350

1,175

2,224

2,489

945

Royalty revenue
Total revenue

28,326

32,837

26,488

27,265

26,313

35,710

35,174

36,255

35,788

36,353

43,616

37,404

36,507

32,014

26,246

31,311

9,469

312

2,422

2,272

3,253

4,094

1,934

1,942

3,565

3,268

2,585

1,535

License and other revenue
Total revenue

0

0

0

0

9,000

0

0

0

0

0

12,500

0

25,000

40,046

3,750

0

6,000

15,000

0

0

30,000

0

0

3,500

265

-

0

0